SeaCrest Wealth Management’s West Pharmaceutical WST Stock Holding History

SeaCrest Wealth Management’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-268	Closed	-$81K	–	1539
2022 Q2	$81K	Buy	+268	New	+$87.2K	0.01%	943
2019 Q2	–	Sell	-189	Closed	-$21K	–	1855
2019 Q1	$21K	Hold	189	–	–	﹤0.01%	1274
2018 Q4	$19K	Sell	189 -1	-0.5%	-$109	﹤0.01%	1261
2018 Q3	$23K	Sell	190 -27	-12%	-$3.03K	﹤0.01%	1329
2018 Q2	$22K	Buy	217 +142	+189%	+$13.1K	﹤0.01%	1327
2018 Q1	$7K	Buy	75 +17	+29%	+$1.59K	﹤0.01%	1713
2017 Q4	$6K	Buy	+58	New	+$5.69K	﹤0.01%	1775

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SeaCrest Wealth Management's WST Position: Q3 2022 in Review

SeaCrest Wealth Management sold out of West Pharmaceutical (WST) in Q3 2022, closing a stake of 268 shares — an estimated $81K sold.

SeaCrest Wealth Management first reported a position in WST in Q4 2017 and held it in 7 quarters. The position peaked at $81K in Q2 2022. 638 funds tracked by Wall St. Rank hold WST as of Q3 2022.

SeaCrest Wealth Management reported no remaining West Pharmaceutical position as of Q3 2022 after selling out during the quarter.
SeaCrest Wealth Management sold 268 West Pharmaceutical shares in Q3 2022, an estimated $81K.
SeaCrest Wealth Management first reported a position in West Pharmaceutical in Q4 2017 and held it in 7 quarters.
SeaCrest Wealth Management's West Pharmaceutical position peaked at $81K in Q2 2022.
638 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2022.

Based on SeaCrest Wealth Management's 13F filing for Q3 2022, filed 15 Nov 2022.